- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02846181
A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-SK-1405
November 21, 2016 updated by: Sanwa Kagaku Kenkyusho Co., Ltd.
The primary objectives of the study are:
- To assess the mass balance recovery after a single PO dose of [14C]-SK-1405
- To provide plasma, urine and faecal samples for metabolite profiling and structural identification
Study Overview
Study Type
Interventional
Enrollment (Actual)
6
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Nottingham, United Kingdom
- Quotient Clinical Ltd.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy males
- Age 30 to 65 years of age
- Body mass index of 18.0 to 30.0 kg/m2
- Must be willing and able to communicate and participate in the whole study
- Must provide written informed consent
- Must have regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools per day)
- Must agree to use an adequate method of contraception
Exclusion Criteria:
- Participation in a clinical research study within the 3 months prior to IMP dose
- Subjects who are study site employees, or immediate family members of a study site or sponsor employee
- Subjects who have previously been enrolled in this study
- Subjects who have been dosed with SK-1405 in the past
- Subjects who are taking, or have taken, antiepileptic and/or antidepressant medication in the 6 months prior to dosing
- Subjects who are taking, or have taken, any prescribed medication in the 28 days prior to dosing, unless judged as not clinically significant by the investigator and sponsor
- Subjects who are taking, or have taken, any over-the-counter medication (with the exception of up to 2,000 mg/day paracetamol/acetaminophen) in the 7 days prior to dosing, unless judged as not clinically significant by the investigator and sponsor
- Use, during the 28 days prior to dosing, of any medicine or herbal remedy (such as St John's wort) known to induce or inhibit CYP enzymes, unless judged as not clinically significant by the investigator and sponsor
- History of any drug or alcohol abuse in the past 2 years
- History of clinically significant neurological conditions
- A QTcF >450 msec at screening, admission or pre-dose (as confirmed by a repeat ECG)
- Regular alcohol consumption in males >21 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)
- Current smokers and those who have smoked within the last 12 months; this includes cigarettes, e-cigarettes and nicotine replacement products. A breath carbon monoxide reading of greater than 10 ppm at screening or admission
- Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, shall participate in the study
- Subjects who have been enrolled in an ADME study in the last 12 months
- Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening
- Clinically significant abnormal biochemistry, haematology or urinalysis as judged by the investigator, including AST, ALT or alkaline phosphatase >1.5 × upper limit of normal confirmed by repeat testing 18. Positive drugs of abuse test result
- Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results
- Evidence of renal impairment at screening, as indicated by an estimated creatinine clearance (CLcr) of <90 mL/min using the Cockcroft-Gault equation
- History of clinically significant psychiatric, cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease as judged by the investigator
- History of gastrointestinal surgery (except appendectomy) or any condition that may affect the absorption, distribution, metabolism or excretion of study drug in the opinion of the investigator
- Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients
- Presence or history of clinically significant allergy (including food or drug allergy) requiring treatment, as judged by the investigator. Hayfever is allowed unless it is active
- Donation or loss of greater than 400 mL of blood within the 3 months prior to IMP dose
- Subjects who have consumed St John's wort, red wine, Seville oranges, grapefruit or grapefruit juice within 7 days prior to dosing. Subjects must be willing to refrain from consuming such products until the last PK sample
- Failure to satisfy the investigator of fitness to participate for any other reason
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Healthy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
14C radioactivity concentration excreted in urine
Time Frame: Every day for 14 days
|
Every day for 14 days
|
14C radioactivity concentration excreted in faeces
Time Frame: Every day for 14 days
|
Every day for 14 days
|
14C radioactivity concentration in whole blood
Time Frame: Every day for 14 days
|
Every day for 14 days
|
14C radioactivity concentration in plasma
Time Frame: Every day for 14 days
|
Every day for 14 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2016
Primary Completion (ACTUAL)
August 1, 2016
Study Completion (ACTUAL)
August 1, 2016
Study Registration Dates
First Submitted
July 11, 2016
First Submitted That Met QC Criteria
July 24, 2016
First Posted (ESTIMATE)
July 27, 2016
Study Record Updates
Last Update Posted (ESTIMATE)
November 23, 2016
Last Update Submitted That Met QC Criteria
November 21, 2016
Last Verified
September 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MO002A
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pruritus
-
Kissei Pharmaceutical Co., Ltd.Completed
-
Toray Industries, IncCompletedUremic PruritusBulgaria, Germany
-
Cara Therapeutics, Inc.CompletedPruritus | Uremic PruritusUnited States
-
Thammasat University HospitalCompletedUremic PruritusThailand
-
Conmed Pharmaceutical & Bio-Medical CorporationChang Gung Memorial Hospital; Kaohsiung Medical University; Tri-Service General... and other collaboratorsCompleted
-
Haisco Pharmaceutical Group Co., Ltd.Completed
-
Kissei Pharmaceutical Co., Ltd.Maruishi PharmaceuticalCompleted
-
Chang Gung Memorial HospitalUnknown
-
Lumosa Therapeutics Co., Ltd.Unknown
-
RDD Pharma LtdWithdrawn
Clinical Trials on [14C]-SK-1405
-
Sanwa Kagaku Kenkyusho Co., Ltd.CompletedUremic Pruritus in Hemodialysis PatientsJapan
-
Sanwa Kagaku Kenkyusho Co., Ltd.CompletedPruritusUnited Kingdom
-
Sanwa Kagaku Kenkyusho Co., Ltd.Completed
-
Molecular Insight Pharmaceuticals, Inc.CompletedProstate CancerUnited States
-
ModernaTX, Inc.Active, not recruiting
-
Indivior Inc.CompletedOpioid Use DisorderUnited States
-
Arcus Biosciences, Inc.Gilead SciencesCompleted
-
BiogenDenali Therapeutics Inc.Completed
-
Denovo Biopharma LLCCompleted
-
Athira PharmaAlturas Analytics, Inc.; Labcorp Drug Development IncCompletedHealthy VolunteersUnited States